Cargando…

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

BACKGROUND/PURPOSE: Optimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination. This investigation aimed to explore the potential prime-boost COVID-19 va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharifi Aliabadi, Leyla, Karami, Manoochehr, Barkhordar, Maryam, Hashemi Nazari, Seyed Saeed, Kavousi, Amir, Ahmadvand, Mohammad, Vaezi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427916/ https://www.ncbi.nlm.nih.gov/pubmed/37593732 http://dx.doi.org/10.3389/fimmu.2023.1237916

Ejemplares similares

Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial
por: Barkhordar, Maryam, et al.
Publicado: (2023)

Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study
por: Barkhordar, Maryam, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks
por: Siddiqui, Amna, et al.
Publicado: (2022)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review
por: Kok, Adinda, et al.
Publicado: (2021)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

Immunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent Model
por: Gupta, Jyoti, et al.
Publicado: (2015)

Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice
por: Zhao, Wei, et al.
Publicado: (2021)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
por: Thompson, Elizabeth A., et al.
Publicado: (2023)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months
por: Low, Ee Vien, et al.
Publicado: (2022)

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
por: Powell, Annabel A, et al.
Publicado: (2021)

Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium
por: Meurisse, Marjan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4dsj678nadu36bk2tcn30c4a4r